Promising Phase 3 Results for Merck-Kelun Lung Cancer Treatment
A targeted chemotherapy developed by Kelun-Biotech and licensed to Merck shows a 65% reduction in tumor progression risk for lung cancer patients in Phase 3 trials.
Editorial Staff about 2 months ago